The ethics of 'fail first': Guidelines and practical scenarios for step therapy coverage policies

Health Affairs

Volumn 33, Issue 10, 2014, Pages 1779-1785

  Nayak, Rahul K ^a   Pearson, Steven D ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PSYCHOSTIMULANT AGENT; PRESCRIPTION DRUG;

ARTICLE; ATTENTION DEFICIT DISORDER; CONCEPTUAL FRAMEWORK; COST CONTROL; DRUG USE; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HYPERCHOLESTEROLEMIA; INAPPROPRIATE PRESCRIBING; MEDICAL ETHICS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; STEP THERAPY COVERAGE POLICY; DRUG COST; ECONOMICS; ETHICS; HEALTH CARE DELIVERY; INSURANCE; PROCEDURES; TREATMENT FAILURE; TREATMENT OUTCOME;

COST SAVINGS; DRUG COSTS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; PRESCRIPTION DRUGS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84907822139     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0516     Document Type: Article

References (28)

1. Hoadley J, Summer L, Hargrave E, Cubanski J. Medicare Part D prescription drug plans: the marketplace in 2013 and key trends, 2006- 2013 [Internet]. Menlo Park (CA): Kaiser Family Foundation; 2013 Dec 11 [cited 2014 Aug 15]. Available from: http://kff.org/medicare/issuebrief/ medicare-part-d-prescriptiondrug-plans-the-marketplace-in-2013-and-key-trends-2006-2013/
2. Pharmacy Benefit Management Institute. 2013-2014 prescription drug benefit cost and plan design report. Plano (TX): PBMI; 2013 Aug.
3. Express Scripts. 2008 drug trend report [Internet]. Maryland Heights (MO): Express Scripts; 2005 Jun [cited 2014 Aug 29]. Available from: http://lab.express-scripts.com/~/ media/previous%20reports %20pdfs/drug%20trend%20report %202008.ashx
4. La. Rev. Stat. Sect. 22:1053 (2011).
5. Miss. Code. Ann. Sect. 83-9-36 (2013).
6. Vt. Stat. Ann. Title 8, Sect. 4089i(e) (2013).
7. Conn. Gen. Stat. Sect. 38a-492i (2012).
8. Centers for Medicare and Medicaid Services. Medicare prescription drug benefit manual [Internet]. Baltimore (MD): CMS. Chapter 6, Part D drugs and formulary requirements [revised 2010 Feb 19; cited 2014 Aug 15]. Available from: http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCov Contra/downloads/chapter6.pdf
9. Leukemia and Lymphoma Society. Testimony in support of MD SB622 (Middleton) health insurance-step therapy or fail-first protocol: Senate Finance Committee [Internet]. Washington (DC): LLS; 2014 Feb 19 [cited 2014 Aug 15]. Available from: http://www.lls.org/content/ nationalcontent/pdf/ways/ MDSB622StepTherapyTestimony
10. Motheral BR. Pharmaceutical steptherapy interventions: a critical review of the literature. J Manag Care Pharm. 2011;17(2):143-55.
11. Motheral BR, Henderson R, Cox ER. Plan-sponsor savings and member experience with point-of-service prescription step therapy. Am J Manag Care. 2004;10(7 Pt 1): 457-64.
12. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36.
13. Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive steptherapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care. 2009; 15(2):123-31.
14. Mark TL, Gibson TM, McGuigan K, Chu BC. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Psychiatry. 2010;167(10):1202-9.
15. Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law MR, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3): w185-95. DOI: 10.1377/hlthaff.27.3.w185.
16. Agency for Healthcare Research and Quality. Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment [Internet]. Rockville (MD): AHRQ; 2011 Oct [cited 2014 Aug 15]. Available from: http://www.effectivehealthcare.ahrq.gov/ehc/products/191/818/ CER44-ADHD_20111021.pdf
17. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98.
18. Ollendorf DA, Colby JA, Pearson SD. Comparative effectiveness of anti-VEGF agents for diabetic macular edema. Int J Technol Assess Health Care. 2013;29(4):392-401.
19. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82(4):661-87.
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
21. Stroup TS. Heterogeneity of treatment effects in schizophrenia. Am J Med. 2007;120(4 Suppl 1):S26-31.
22. Singh JA, Cameron DR. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults-an update. J Manag Care Pharm. 2012;18(4 Suppl C):S1-18.
23. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011;183(16):31189-202.
24. Agency for Healthcare Research and Quality. Combination therapy versus intensification of statin monotherapy: an update [Internet]. Rockville (MD): AHRQ; 2014 Feb [cited 2014 Aug 15]. Available from: http://effectivehealthcare.ahrq.gov/ehc/products/531/1860/highcholesterol-medicines-updatereport-140211.pdf
25. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hannanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87.
26. Nemlekar P, Shepherd M, Lawson K, Rush S.Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs. J Manag Care Pharm. 2013;19(8):602-8.
27. Cha AE. AIDS advocates say drug coverage in some marketplace plans is inadequate. Washington Post. 2013 Dec 9.
28. Pearson CF. Consumers face more hurdles to accessing drugs in exchange plans compared to employer coverage [Internet]. Washington (DC): Avalere Health; 2014 Mar 24 [cited 2014 Aug 15]. Available from: http://avalerehealth.net/expertise/ life-sciences/insights/morecontrols-on-drug-access-inexchanges